GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Concept Inc (NAS:VERO) » Definitions » EV-to-EBITDA

Venus Concept (Venus Concept) EV-to-EBITDA : -3.01 (As of May. 11, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Venus Concept EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Venus Concept's enterprise value is $78.62 Mil. Venus Concept's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-26.11 Mil. Therefore, Venus Concept's EV-to-EBITDA for today is -3.01.

The historical rank and industry rank for Venus Concept's EV-to-EBITDA or its related term are showing as below:

VERO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.09   Med: -3.03   Max: -0.64
Current: -3.01

During the past 9 years, the highest EV-to-EBITDA of Venus Concept was -0.64. The lowest was -15.09. And the median was -3.03.

VERO's EV-to-EBITDA is ranked worse than
100% of 483 companies
in the Medical Devices & Instruments industry
Industry Median: 16.47 vs VERO: -3.01

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Venus Concept's stock price is $0.68. Venus Concept's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.850. Therefore, Venus Concept's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Venus Concept EV-to-EBITDA Historical Data

The historical data trend for Venus Concept's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Concept EV-to-EBITDA Chart

Venus Concept Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -6.24 -2.01 -12.00 -2.76 -3.12

Venus Concept Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.76 -2.66 -2.81 -3.45 -3.12

Competitive Comparison of Venus Concept's EV-to-EBITDA

For the Medical Devices subindustry, Venus Concept's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Concept's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Concept's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Venus Concept's EV-to-EBITDA falls into.



Venus Concept EV-to-EBITDA Calculation

Venus Concept's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=78.623/-26.113
=-3.01

Venus Concept's current Enterprise Value is $78.62 Mil.
Venus Concept's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Concept  (NAS:VERO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Venus Concept's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.68/-6.850
=At Loss

Venus Concept's share price for today is $0.68.
Venus Concept's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.850.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Venus Concept EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Venus Concept's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Concept (Venus Concept) Business Description

Traded in Other Exchanges
N/A
Address
235 Yorkland Boulevard, Suite 900, Toronto, ON, CAN, M2J 4Y8
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Heal, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
Executives
Anthony Natale director 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Ross Portaro officer: President Global Sales 235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Michael Willingham Masters 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Silva Rajiv De director, officer: Chief Executive Officer 1400 ATWATER DRIVE, MALVERN PA 19355
Stanley Tyler Hollmig director 235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Hemanth Jacob Varghese officer: President/Chief Bus. Officer 330 JOICEY BOULEVARD, TORONTO A6 M5M2W1
Marlin Fund, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Capital Management Llc 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Fund Iii, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Master Fund Offshore Ii, Lp 10 percent owner WAYSTONE CORP SV (CAYMAN) LTD, STE 5B201, FL 2, 1 NEXUS WAY, CAMANA BAY, BOX 1344, GRAND CAYMAN E9 KY1-1108
Mss Vc Spv Lp 10 percent owner C/O MASTERS SPECIAL SITUATIONS, LLC, 3060 PEACHTREE ROAD, NW, STE.1425, ATLANTA GA 30305
Marlin Fund Ii, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Special Situations, Llc 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Penna Domenic Della officer: Chief Financial Officer 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Anna Georgiadis officer: VP, Global HR 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8

Venus Concept (Venus Concept) Headlines

From GuruFocus

Venus Concept Announces 1-for-15 Reverse Stock Split

By sperokesalga sperokesalga 05-11-2023

Venus Concept Receives New FDA 510(k) Clearance for Venus BlissMAX

By GuruFocusNews GuruFocusNews 04-28-2022